
### [NCIT:C8854](http://purl.obolibrary.org/obo/NCIT_C8854)
**Label:** Stage I Diffuse Large B-Cell Lymphoma

**Subclasses:** [NCIT:C8876](http://purl.obolibrary.org/obo/NCIT_C8876) (Stage I Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8078](http://purl.obolibrary.org/obo/NCIT_C8078) (Stage I Adult Immunoblastic Lymphoma), [NCIT:C8928](http://purl.obolibrary.org/obo/NCIT_C8928) (Stage I Centroblastic Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 53.75%
- [NCIT:C27966](http://purl.obolibrary.org/obo/NCIT_C27966) (Stage I) 52.27%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39897](http://purl.obolibrary.org/obo/NCIT_C39897) (Prostate Ductal Adenocarcinoma, Solid Pattern))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39896](http://purl.obolibrary.org/obo/NCIT_C39896) (Prostate Ductal Adenocarcinoma, Papillary Pattern))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39895](http://purl.obolibrary.org/obo/NCIT_C39895) (Prostate Ductal Adenocarcinoma, Cribriform Pattern))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3989](http://purl.obolibrary.org/obo/NCIT_C3989) (Parathyroid Hyperplasia))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39885](http://purl.obolibrary.org/obo/NCIT_C39885) (Acinar Prostate Adenocarcinoma, Lymphoepithelioma-Like Variant))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39880](http://purl.obolibrary.org/obo/NCIT_C39880) (Acinar Prostate Adenocarcinoma, Atrophic Variant))) 37.63%


